ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (" ImmuneOnco ", Stock code: 1541.HK) was officially listed on the Main Board of the Hong Kong Stock Exchange on September 5.

 

As a clinical-stage biotechnology company dedicated to developing innovative tumor immunotherapies, ImmuneOnco is one of the few biotechnology companies in the world capable of taking a systematic approach to the treatment of cancer using the innate and adaptive immune systems.

 

ImmuneOnco's intermediary team for the IPO includes:

Morgan Stanley and CICC are co-sponsors;

Cooley is the company's legal counsel in Hong Kong and the United States, while JunHe LLP is the company's legal counsel in China;

Kirkland & Ellis is the Hong Kong and US legal counsel of the underwriters, while Jingtian & Gongcheng is the China legal counsel of the underwriters;

Deloitte provides audit services;

Frost & Sullivan is an industry consultant.